Mulpleta, Mulpleo (previously lusutrombopag shionogi)(lusutrombopag)
Lusutrombopag, Mulpleo, Mulpleta (lusutrombopag) is a small molecule pharmaceutical. Lusutrombopag was first approved as Mulpleta on 2018-07-31. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. The pharmaceutical is active against thrombopoietin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Mulpleta
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mulpleta | New Drug Application | 2020-10-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| thrombocytopenia | HP_0001873 | D013921 | D69.6 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 4 | 1 | 1 | — | 6 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | 1 | 1 | — | 2 |
| Aplastic anemia | D000741 | — | D61.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 3 | — | — | — | 3 |
| Thrombocytopenic purpura | D011696 | — | — | — | 1 | — | — | — | 1 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lusutrombopag |
| INN | lusutrombopag |
| Description | Lusutrombopag is a member of cinnamic acids. |
| Classification | Small molecule |
| Drug class | thrombopoetin agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC |
Identifiers
| PDB | — |
| CAS-ID | 1110766-97-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107831 |
| ChEBI ID | — |
| PubChem CID | 49843517 |
| DrugBank | DB13125 |
| UNII ID | 6LL5JFU42F (ChemIDplus, GSRS) |
Target
Agency Approved
MPL
MPL
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 236 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use